Document is current
Any future updates will be listed below
-
Authors
Rubio-Nazabal, Eduardo https://orcid.org/0000-0003-3049-987X
Majoie, Marian
Schulz, Anne-Liv
Brock, Fiona
Leunikava, Iryna
Bourikas, Dimitrios
Steinhoff, Bernhard J. https://orcid.org/0000-0001-5995-5862
-
Funding
Funding for this research was provided by:
UCB Pharma
- License Information
-
More Information
Article History
Received: 25 September 2024
Accepted: 11 December 2024
First Online: 20 February 2025
Declarations
:
: Eduardo Rubio-Nazabal has received honoraria from BIAL, Eisai, and UCB for speaking. Marian Majoie has received financial compensation through her institution for participating in contract research from Eisai, GW Pharmaceuticals, UCB, and Zogenix. Anne-Liv Schulz, Fiona Brock, Iryna Leunikava, and Dimitrios Bourikas are employees of UCB. Anne-Liv Schulz and Dimitrios Bourikas have received UCB stocks from their employment. Bernhard J. Steinhoff has received honoraria for consulting (from Angelini Pharma, Arvelle Therapeutics, B. Braun Melsungen, Desitin, Eisai, GW Pharmaceuticals, Neuraxpharm, and UCB), for serving on a scientific advisory board (from Arvelle Therapeutics, GW Pharmaceuticals, UCB, and Zogenix), and for speaking (from Arvelle Therapeutics, Desitin, Eisai, Hikma Pharmaceuticals, UCB, and Zogenix), and has received research support from Eisai, SK Life Science, and UCB.
: The study protocol was reviewed and approved by an Institutional Review Board/Independent Ethics Committee (see Institutional Review Board/Independent Ethics Committee appendix in the Supplementary Material), per country-specific regulations. Written data consent was obtained from the patient, parent(s), or legal representative before study participation, in accordance with local regulations and the Declaration of Helsinki.
